Company news
Gyre Therapeutics, Inc. news in 2025
Gyre Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
November 6, 2025
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
October 14, 2025
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
October 13, 2025
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
August 21, 2025
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
August 10, 2025
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
June 9, 2025
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 28, 2025
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
May 21, 2025
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
May 21, 2025
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
May 21, 2025
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
March 30, 2025
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
March 26, 2025
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 16, 2025
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
January 5, 2025
Decks in 2025
- H.C. Wainwright Global Investment Conference 2025
Conference · 18 slides · Sep 10, 2025
- Technical Presentation (May 2025)
Technical · 28 slides · May 22, 2025
- Investor Presentation (April 2025)
Investor deck · 24 slides · Apr 28, 2025